MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ ImmVira announced to appoint Dr. Howard L. Kaufman as Consulting Medical Advisor. Dr. Kaufman s expertise in scientific research and clinical.
/PRNewswire/ On August 1, 2022, U.S. time, ImmVira s brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has.
/PRNewswire/ ImmVira s breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has.